GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments. The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners [...]